GAITHERSBURG, Md., Nov. 4, 2024
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company
advancing protein-based vaccines with its Matrix-M™ adjuvant, today
announced it will report its third quarter 2024 financial results
and operational highlights at 8:30 a.m.
Eastern Time (ET) on Tuesday,
November 12, 2024. Details of the event and replay are as
follows:
|
Conference call
details:
|
|
|
Date:
|
November 12,
2024
|
|
Time:
|
8:30 a.m. U.S.
ET
|
|
URL to register
phone:
|
https://emportal.ink/3Y6irHG
|
|
Dial-in
number:
|
(800) 836-8184
(Domestic) or
|
|
(+1) (646) 357-8785
(International)
|
|
Webcast:
|
ir.novavax.com/events
|
- Participants can join the conference call without operator
assistance by registering and entering their phone number with the
above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the
call by an operator and will be prompted to request to join the
Novavax, Inc. call.
- To ensure a timely connection, it is recommended that
participants join at least 10 minutes prior to the scheduled
webcast.
|
Replay
details:
|
|
Date:
|
Available starting at
11:30 a.m. ET, November 12, 2024, until 11:59 p.m. U.S. ET,
November 19, 2024
|
|
Dial-in
number:
|
(888) 660-6345
(Domestic) or
|
|
(+1) (646) 517-4150
(International)
|
|
Passcode:
|
62491 #
|
|
Webcast:
|
ir.novavax.com/events,
until December 12, 2024
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to help protect against serious infectious
diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. The Company's
portfolio includes its COVID-19 vaccine and its pipeline includes
COVID-19-Influenza Combination and stand-alone influenza
vaccine candidates. In addition, Novavax's adjuvant is included in
the University of Oxford and Serum
Institute of India's R21/Matrix-M
malaria vaccine. Please visit novavax.com and
LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
202-709-5563
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-third-quarter-2024-financial-results-and-operational-highlights-on-november-12-2024-302295599.html
SOURCE Novavax, Inc.